ANTHIM
PeakmAbobiltoxaximab
BLAINJECTIONINJECTABLE
Approved
Mar 2016
Lifecycle
Peak
Competitive Pressure
30/100
Data completeness
4/8 — Partial
ANTHIM (obiltoxaximab) is anthrax protective antigen-directed antibody interactions [moa]. Approved for inhalational anthrax due to b, treat meningitis. First approved in 2016.
Drug data last refreshed 11h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ANTHIM (obiltoxaximab) is a monoclonal antibody directed against anthrax protective antigen that functions by blocking the toxin's mechanism of action. It is indicated for treatment of inhalational anthrax and anthrax meningitis in adult and pediatric patients. The drug works by binding to protective antigen and preventing formation of the lethal toxin complex.
Peak
Peak lifecycle stage suggests stable commercial operations with established market presence, though limited public data indicates niche positioning and smaller dedicated team.
Mechanism of Action
Anthrax Protective Antigen-directed Antibody Interactions
Pharmacologic Class:
Anthrax Protective Antigen-directed Antibody
Indications (2)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.